What if the real breakthrough in healthcare AI isn’t faster algorithms—but trust, ethics, and knowing when not to automate? In this episode of Scouting for Growth, Sabine VdL sits down with Dr Andrée Bates—neuroscientist, entrepreneur, and founder of Eularis—to explore how artificial intelligence is fundamentally reshaping healthcare, pharmaceuticals, and medical decision-making. This is not a speculative discussion about AI’s potential. It’s a grounded, experience-led conversation about what’s already changing—and what must change next if innovation is to be both effective and responsible. Dr Bates has been operating at the intersection of science, technology, and commercial healthcare since the early 1990s. Long before AI became a boardroom buzzword, she was building digital health businesses and applying advanced analytics to real-world medical problems. Eularis itself was born from a precise question: how can mathematics and data be used to improve commercial and clinical outcomes in the pharmaceutical industry? That question has since evolved into AI-driven work spanning R&D, clinical trials, and medical affairs for the world’s top 50 pharma companies. A central theme of the episode is demystification. AI, Dr Bates reminds us, is not a single technology. It’s an umbrella term covering many different techniques—each with different strengths, limitations, and ethical implications. Generative AI, in particular, doesn’t “invent” from nothing. It recombines patterns from the data it has been trained on, creating new outputs based on learned relationships. Understanding that distinction is critical—especially in healthcare, where decisions carry real human consequences. The conversation moves quickly into impact. AI is already transforming drug development timelines, with models capable of predicting—at remarkably high accuracy—whether a drug is likely to succeed long-term. In other cases, AI has enabled the repurposing of existing drugs, dramatically accelerating response times in crises like Covid. These are not marginal gains. They are structural shifts in how healthcare innovation happens. But progress introduces new risks. One of the most striking discussions centres on digital authenticity. As AI-generated voice, video, and imagery become indistinguishable from reality, Dr Bates argues we will need new forms of digital certification—something akin to a biometric fingerprint—to verify what, and who, is real. In healthcare, where trust is foundational, this challenge cannot be ignored. Ethics runs throughout the episode—not as a constraint, but as an enabler of sustainable innovation. AI will only scale in healthcare if patients, clinicians, regulators, and institutions trust how it is used. That requires transparency, governance, and leadership willing to ask difficult questions early. This episode is essential listening for healthcare executives, life sciences leaders, policymakers, and technologists navigating AI adoption under intense regulatory, ethical, and commercial pressure. It’s a reminder that transformation in healthcare isn’t driven by technology alone—it’s driven by judgment. Because in healthcare, the future doesn’t belong to those who move fastest— but to those who move intelligently, ethically, and with humanity at the centre. And that’s exactly what Scouting for Growth is here to uncover.